13 results
S-1/A
EX-10.9
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
buffers and cell culture media) not licensed by Hospital to Company hereunder (“Other Component”) to form a product that is a combination of a
Product … with routine components that may include common buffers and cell culture media) during a given Reporting Period, then the royalty due under Section 4.5
S-1
EX-10.9
CADL
Candel Therapeutics Inc
25 Jun 21
IPO registration
5:28pm
routine component, including common buffers and cell culture media) not licensed by Hospital to Company hereunder (“Other Component”) to form a product … product or as its own product combined with routine components that may include common buffers and cell culture media) during a given Reporting Period
DEF 14A
CADL
Candel Therapeutics Inc
2 Sep 22
Definitive proxy
8:30am
to contribute positively to the collaborative culture among board members, and their knowledge of our business and understanding of the competitive landscape … our executive officers with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executive
S-1
EX-10.8
CADL
Candel Therapeutics Inc
25 Jun 21
IPO registration
5:28pm
means whatsoever.
1.2 “ATCC Agreement” means the material transfer agreement entered into between Periphagen and the American Type Culture Collection
10-K/A
9e9ri2y 62o1bmh
1 May 23
Annual report (amended)
8:01am
S-1
hia0rya31u7h0ufzipv
25 Jun 21
IPO registration
5:28pm
DRS/A
z2yjzaa
31 Mar 21
Draft registration statement (amended)
12:00am
S-1/A
hf6e17ltu3g9 a2
16 Jul 21
IPO registration (amended)
6:07am
424B4
rqpeitpgn nj
28 Jul 21
Prospectus supplement with pricing info
4:02pm
10-K
9l76lu
29 Mar 22
Annual report
8:46am
- Prev
- 1
- Next